Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5
10.4078/jrd.2019.26.2.118
- Author:
Eeunyoung AHN
1
;
Sunggun LEE
;
Han Na LEE
;
Seung Geun LEE
;
Min Wook SO
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. thalsdnrso@naver.com
- Publication Type:Original Article
- Keywords:
Gout;
Febuxostat;
Chronic kidney disease
- MeSH:
Dizziness;
Exanthema;
Febuxostat;
Follow-Up Studies;
Glomerular Filtration Rate;
Gout;
Humans;
Renal Insufficiency, Chronic;
Uric Acid
- From:Journal of Rheumatic Diseases
2019;26(2):118-123
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To compare efficacy and safety of febuxostat in gouty patients with chronic kidney disease (CKD) stage 3 and stage 4/5. METHODS: Age and sex matched patients with CKD stage 3 and stage 4/5 who were diagnosed with gout were included. The dose of febuxostat was increased according to serum uric acid (sUA) level. Adherence, the number of gout attack, the change of sUA, the change of estimated glomerular filtration rate (eGFR) and adverse events (AEs) were evaluated for 12 months. RESULTS: There were no significant differences in the baseline variables between CKD stage 3 and CKD stage 4/5. Disease duration was longer and baseline sUA was higher in the CKD stage 4/5. There were no significant differences in the mean sUA at the last follow-up, the number of patients who reached the sUA target of 6 mg/dL and the number of gout attack between the groups. There were no significant differences in the change of eGFR and decrease of eGFR between the groups. There were 2 cases of AEs. One patient in CKD stage 3 had maculopapular rash and one patient in CKD stage 4/5 had dizziness. The AEs were subsided after febuxostat was stopped. CONCLUSION: Febuxostat was efficacious and well tolerated in gout patients with CKD stage 4/5.
